A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients

LC Schneider, R Rachid, J LeBovidge, E Blood… - Journal of allergy and …, 2013 - Elsevier
Background Peanut allergy is a major public health problem that affects 1% of the
population and has no effective therapy. Objective To examine the safety and efficacy of oral
desensitization in peanut-allergic children in combination with a brief course of anti-IgE mAb
(omalizumab [Xolair]). Methods We performed oral peanut desensitization in peanut-allergic
children at high risk for developing significant peanut-induced allergic reactions.
Omalizumab was administered before and during oral peanut desensitization. Results We …